PTI’s Remoxy: Negative FDA Panel Review May Be The End Of Abuse-Deterrent Opioid's Road

 
• By Sue Sutter
Dead end sign in the desert.
Concerns about Remoxy's similarities to Endo's now-withdrawn Opana ER could mean the end of the long-acting opioid's development.

More from New Products

More from Scrip